P272 Improvements in exacerbation rates with single inhaler triple therapy versus dual ics/laba therapy in patients with advanced chronic obstructive pulmonary disease (copd): subgroup analyses of the phase iii fulfil study

E Hilton,R Birk,Mt Dransfield,Gj Criner,Da Lomas,Da Lipson,D Halpin,C-Q Zhu,N Brealey

doi:10.1136/thoraxjnl-2017-210983.414

P272 Improvements in exacerbation rates with single inhaler triple therapy versus dual ics/laba therapy in patients with advanced chronic obstructive pulmonary disease (copd): subgroup analyses of the phase iii fulfil study

E Hilton, R Birk + Show 7 more

Open Access

https://doi.org/10.1136/thoraxjnl-2017-210983.414

Copy DOI

Journal: Thorax

Publication Date: Nov 15, 2017

Affiliation: University of Alabama at Birmingham, Temple University, University College London, University of Pennsylvania, Royal Devon and Exeter Hospital

#Fluticasone Furoate/umeclidinium/vilanterol #Long Acting Beta Agonists + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Results from FULFIL have shown statistically significant improvements in lung function and health-related quality of life, and a reduction in exacerbation rates with once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100 µg/62.5 µg/25...

Full Text